Evidence map›Paper›PMID 23341290›Full record

ReviewClinical drug investigation2013

Iobitridol: a review of its use as a contrast medium in diagnostic imaging.

Paul L McCormack

Abstract readComparative StudyReview
PubMed Publisher
In one paragraph

Review in Clinical drug investigation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Paul L McCormackAdis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand. cdi@adis.com

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Iobitridol is a water-soluble, non-ionic, monomeric, low-osmolar, iodine-based contrast medium in which the potential for interaction with membrane proteins in the body has been minimized by stable masking of the molecule's lipophilic tri-iodinated benzene ring. It is approved in various countries worldwide for use as an intravascular contrast medium in adults and children. This article reviews the diagnostic efficacy and tolerability of iobitridol use as an intravascular contrast agent in diagnostic imaging, and briefly overviews its pharmacological properties. In randomized controlled trials, the global image quality and diagnostic quality with iobitridol did not differ from those with other low-osmolar contrast media (iohexol, iopromide, iopamidol, iomeprol and ioxaglate) or the iso-osmolar contrast medium iodixanol in adults or children undergoing radiographic imaging. Large post-marketing surveillance studies have confirmed that iobitridol produces good or excellent opacification and is an effective contrast agent in the vast majority of patients. Iobitridol was generally well tolerated and had a tolerability profile similar to that of other low-osmolar and iso-osmolar contrast media. Thus, iobitridol is an effective intravascular agent for contrast enhancement in diagnostic imaging.

Indexed as

Contrast MediaAdultAnimalsChildDiagnostic ImagingHumansIohexolOsmolar ConcentrationSolubilityContrast MediaiobitridolIohexol

Identifiers

PMID23341290
OpenAlexW2047588478

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.